Safety, Tolerability and Pharmacokinetics of a Monoclonal Antibody Specific to B-and T-Lymphocyte Attenuator (BTLA) as Monotherapy and in Combination With an Anti-PD1 Monoclonal Antibody for Injection in Subjects With Advanced Malignancies

NCT04137900 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

499

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Unresectable Solid Tumor
Metastatic Solid Tumor

Interventions

DRUG: TAB004
DRUG: Toripalimab

Sponsor

TopAlliance Biosciences

Collaborators

[object Object]
[object Object]